SCHEMBL6318226

SCHEMBL6318226

CN(C(=O)OC(C)(C)C)[C@H](Cc1ccccc1)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 2/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ ATM Q13315 1/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ ITGA4 P13612 1/20 0.42
▸ ITGB7 P26010 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ CTSS P25774 2/20 0.41
▸ CTSL P07711 1/20 0.41
▸ CTSB P07858 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ SLC7A5 Q01650 1/20 0.40
▸ AAK1 Q2M2I8 1/20 0.40
▸ ABCB1 P08183 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ITGB3 P05106 1/20 0.39
▸ ITGA2B P08514 1/20 0.39
▸ ACE P12821 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11358027 1.00 REN (0.45) RENMMP13ATMEPHX1ITGA4
SCHEMBL2476924 0.89 MMP13 (0.46) RENMMP13ATMITGA4ITGB7
SCHEMBL1401042 0.89 MMP13 (0.46) RENMMP13ATMITGA4ITGB7
SCHEMBL65502 0.89 MMP13 (0.46) RENMMP13ATMITGA4ITGB7
SCHEMBL7661910 0.88 MMP13 (0.44) RENMMP13CTSSCTSKAAK1
SCHEMBL8164713 0.87 REN (0.48) RENMMP13ATMITGA4ITGB7
SCHEMBL6326103 0.86 REN (0.45) RENMMP13ATMITGA4ITGB7
SCHEMBL27909457 0.86 ATM (0.42) RENATMEPHX1ITGA4ITGB7
SCHEMBL3777215 0.85 LDHA (0.46) MMP13EPHX1ALDH1A1AAK1L3MBTL1
SCHEMBL6600189 0.85 REN (0.49) RENMMP13ATMITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 REN 261/4885MMP13 2217/4885ATM 4618/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR REN 263/4885MMP13 2288/4885ATM 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback